+

WO1996011929A1 - Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b - Google Patents

Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b Download PDF

Info

Publication number
WO1996011929A1
WO1996011929A1 PCT/EP1995/003887 EP9503887W WO9611929A1 WO 1996011929 A1 WO1996011929 A1 WO 1996011929A1 EP 9503887 W EP9503887 W EP 9503887W WO 9611929 A1 WO9611929 A1 WO 9611929A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrrolo
pyridylcarbonyl
methyl
formula
indole
Prior art date
Application number
PCT/EP1995/003887
Other languages
English (en)
Inventor
Frederick Cassidy
Ian Hughes
Shahzad Sharooq Rahman
David James Hunter
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of WO1996011929A1 publication Critical patent/WO1996011929A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • This invention relates to compounds having pharmacological activity, to a process for their preparation, to compositions containing them and to their use in the treatment of mammals.
  • WO 95/01976 (SmithKline Beecham plc) describes indoline derivatives which are described as possessing 5HT 2C receptor antagonist activity.
  • a structurally distinct class of compounds has now been discovered, which have been found to have 5HT 2C receptor antagonist activity.
  • Certain compounds of the invention also exhibit 5HT 2B antagonist activity.
  • 5HT 2C/2B receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS as well as microvascular diseases such as macular oedema and retinopathy.
  • the present invention provides a compound of formula (I) or a salt, solvate or hydrate thereof:
  • A, B, C and D are all carbon atoms or one of A, B, C or D is nitrogen and the others are all carbon;
  • E is oxygen, sulphur, CH 2 or NR 1 where R 1 is hydrogen or C 1 -6 alkyl;
  • R 2 is hydrogen, halogen, C 1 -6 alkyl, C 1-6 alkylthio, nitro, CF 3 , cyano, NR 4 R 5 ,
  • R 3 is a group of formula (i) in which:
  • X and Y are both nitrogen, one is nitrogen and the other is carbon or a CH group or one is a CH group and the other is carbon or a CH group;
  • R 8 and R 9 groups are independently C 1-6 alkyl optionally substituted by one or more halogen atoms, C 2-6 alkenyl, C 3-6 cycloalkyloxy, C 3-6 cycloalkylC 1-6 alkoxy,
  • R 10 and R 1 1 are independently hydrogen or C 1-6 alkyl
  • R 3 is a group of formula (ii):
  • R 8 and R 9 are as defined in formula (i), X and Y are both nitrogen, one is nitrogen and the other is a CH group or X and Y are both CH groups;
  • R 12 is hydrogen or C 1-6 alkyl
  • R 3 is a group of formula (iii):
  • R 8 , R 9 , X and Y are as defined for formula (i) and Z is oxygen, sulphur, CH 2 or NR 13 where R 13 is hydrogen or C 1-6 alkyl.
  • C 1-6 alkyl moieties whether alone or as pan of another group can be straight chain or branched.
  • A, B, C and D are all carbon atoms giving an indole ring, or one of A, B, C or D is nitrogen and the others are all carbon giving an azaindole ring, that is to say, a 4-, 5-, 6- or 7-azaindole ring.
  • A, B and C are all carbon atoms and D is a nitrogen atom, giving a 7-azaindole ring, also known as a pyrrolo[2,3-b]pyridine ring
  • E is NR 1 where R 1 is hydrogen.
  • R 2 is hydrogen
  • R 3 is a group of formula (i).
  • X and Y form part of a phenyl ring, that is to say one of X or Y is carbon and the other is a CH group or both of X and Y are CH groups.
  • R 3 is an indoline ring, that is to say a group of formula (A):
  • R 8 and R 9 form part of an aromatic ring
  • suitable rings include thiophene, furan and pyrrole rings.
  • Preferred R 8 and R 9 groups which can be the same or different, include C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, halogen, CF3, and CO 2 R 6 where R 6 is hydrogen or C 1-6 alkyl.
  • R 8 is trifluoromethyl and R 9 is C 1-6 alkylthio, for example methylthio.
  • Particularly preferred compounds of formula (I) include:
  • N-(1-Methyl-5-indolyl)-1-methylpyrrolof2,3-b]pyridine-3-carboxamide 2,3-Dihydro-5-methyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole, 2,3-Dihydro-5-ethyl-1-(1-methyl-3-pyrrolo[2,3-b]pyridylcarbonyl)pyrrolo[2,3-f]indole, 2,3-Dihydro-5-methyl-1-(3-pyrrolo[3,2-b]pyridylcarbonyl)pyrrolor2,3-f]indole,
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, ic and methanesulphonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, ic and methanesulphonic.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II):
  • A, B, C, and D are as defined in formula (I)
  • E is as defined in formula (I) or is a group NR 1
  • L is a leaving group and X is hydrogen or a metal atom
  • the variables, R 1 ' , R 2' and R 3 are R 1 , R 2 and R 3 respectively, as defined in formula (I), or groups convertible thereto, and thereafter optionally and as necessary and in any appropriate order, convening any R 1' , R 2' and R 3' when other than R 1 , R 2 and R 3 respectively to R 1 , R 2 and R 3 , interconverting R 1 , R 2 and R 3 and forming a pharmaceutically acceptable salt thereof.
  • L is a leaving group such as halogen, in particular chloro.
  • X is hydrogen or a metal atom such as lithium or magnesium.
  • R 1 is hydrogen
  • C 1 -6 alkyl group by conventional alkylation using 1 molar equivalent of a C 1 -6 alkyl halide and 1 molar equivalent of a suitable base in an inert solvent.
  • R 2 ' , A, B, C, D and E are as defined in formula (II) using standard procedures.
  • compositions may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT 2B/2C receptor antagonist activity and are believed to be of potential use fo the treatment or prophylasis of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS as well as microvascular diseases such as macular oedema and retinopathy.
  • the invention further provides a method of treatment or prophylaxis of the above disorders, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis the above disorders.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • aqueous or oily suspension solutions, emulsions, syrups or elixirs
  • a dry product for reconstitution with water or other suitable vehicle before use.
  • preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • suspending agents such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.01 to 100 mg; and such therapy may extend for a number of weeks or months.
  • N-acetyl-5-nitroindoline (D1) (4 g), excess acetaldehyde (20 ml) and 5% Pd/C (0.5 g) in ethanol (150 ml) was hydrogenated at a pressure of 45 psi for 18 h.
  • the mixture was then filtered through Kieselguhr, and evaporated to dryness to afford crude N-acetyl-5-diethylaminoindoline as a white solid (4.3 g). This was dissolved in cone. HCl (5 ml) and heated over a steambath for 0.5 h.
  • the solution was then basified by dropwise addition of aqueous K 2 CO 3 and extracted with chloroform(3 ⁇ 20 ml).
  • the indole (D10) (67.63g, 0.315 mol) was treated with sodium cyanoborohydride (40 g, 0.637 mol) in glacial acetic acid (500 ml) using standard methodology to afford the title indoline (67.73g, 99%) as an off-white solid.
  • N-(1-Methyl-5-indolyl)pyrrolo[2,3-b]pyridine-3-carboxamide (E6) A suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid 1 (162 mg, 1 mmol) in thionyl chloride (2 ml) was heated under reflux for 2 h then kept at room temperature overnight. The mixture was evaporated to dryness, then a suspension of the residue in dichloromethane (10 ml) was added in portions to a solution of 1-methyl-5-aminoindole (146 mg, 1 mmol) and triethylamine (0.28 ml, 2 mmol) in dichloromethane (10 ml).
  • N-(1-Methyl-5-indolyl)pyrrolo[2,3-c]pyridine-3-carboxamide (E14) A suspension of pyrrolo[2,3-c]pyridine-3-carboxylic acid 1 (118 mg, 0.73 mmol) in thionyl chloride (5 ml) was heated under reflux overnight at room temperature. The mixture was evaporated to dryness, then a suspension of the residue in dichloromethane (5 ml) was added in portions to a solution of 1-methyl-5-aminoindole (106 mg, 0.73 mmol) and triethylamine (221 mg, 2.2 mmol) in dichloromethane (10 ml).
  • 6-Chloro-5-methyl-1-(3-pyrrolo[2,3-b]pyridylcarbonyl)indoline E19
  • a suspension of pyrrolo[2,3-b]pyridine-3-carboxylic acid (109 mg, 0.67 mmol) in thionyl chloride (5 ml) was stined for 18 h at room temperature. Excess thionyl chloride was evaporated in vacuo and the residue dissolved in dichloromethane was added to a solution of 6-chloro-5-methylindoline (see WO 95/01976) (90 mg, 0.53 mmol) and triethylamine (16 mg, 1.6 mmol) in dichloromethane (5 ml).
  • the compounds of examples 1 to 20 have pKi values of 5.2 to 8.3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On décrit des composés indoles et indolines possédant une activité pharmacologique, un procédé de préparation de ceux-ci, des compositions les contenant ainsi que leur utilisation dans le traitement de troubles du système nerveux central (antagonistes de 5HT 2C/2B).
PCT/EP1995/003887 1994-10-12 1995-10-02 Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b WO1996011929A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420521A GB9420521D0 (en) 1994-10-12 1994-10-12 Novel compounds
GB9420521.8 1994-10-12

Publications (1)

Publication Number Publication Date
WO1996011929A1 true WO1996011929A1 (fr) 1996-04-25

Family

ID=10762700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/003887 WO1996011929A1 (fr) 1994-10-12 1995-10-02 Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b

Country Status (2)

Country Link
GB (1) GB9420521D0 (fr)
WO (1) WO1996011929A1 (fr)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001058869A2 (fr) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
DE10053275A1 (de) * 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
WO2002034747A1 (fr) * 2000-10-27 2002-05-02 Elbion Ag Nouveaux 7-azaindoles, leur utilisation en tant qu'inhibiteurs de la phosphodiesterase 4 et leur procede de production
WO2002062423A1 (fr) * 2001-02-02 2002-08-15 Bristol-Myers Squibb Company Composition et activite antivirale de derives de piperazine azaindoleoxoacetique substitues
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
WO2004094416A1 (fr) * 2003-04-24 2004-11-04 Elbion Ag 7-azaindoles et leur utilisation comme produits therapeutiques
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
FR2865208A1 (fr) * 2004-01-16 2005-07-22 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
WO2006009755A2 (fr) * 2004-06-17 2006-01-26 Plexxikon, Inc. Composes modulant l'activite de c-kit
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
ES2274725A1 (es) * 2005-11-08 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
US7348337B2 (en) 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7354924B2 (en) 2001-02-02 2008-04-08 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US7531552B2 (en) 2002-02-14 2009-05-12 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic pyrrolidine derivatives
US7589206B2 (en) 2004-06-09 2009-09-15 Glaxo Group Limited Pyrrolopyridine derivatives
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
US7728140B2 (en) 2003-12-24 2010-06-01 Pfizer Italia S.R.L. Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them
EP2202222A2 (fr) 2005-11-08 2010-06-30 Laboratorios Del Dr. Esteve, S.A. Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7829711B2 (en) 2004-11-09 2010-11-09 Bristol-Myers Squibb Company Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7888508B2 (en) 2003-12-24 2011-02-15 Pfizer Italia S.R.L. Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors
US7902204B2 (en) 2003-11-26 2011-03-08 Bristol-Myers Squibb Company Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7964603B2 (en) 2007-07-19 2011-06-21 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
US8039486B2 (en) 2003-07-01 2011-10-18 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US8138210B2 (en) 2006-07-31 2012-03-20 Laboratorios Del Dr. Esteve, S.A. Substituted indanyl sulfonamide compounds, their preparation and use as medicaments
EP2497770A1 (fr) 2002-08-07 2012-09-12 Bristol-Myers Squibb Company Composition et activité antivirale de dérivés de pipérazine azaindoléoxoacétique substitués
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
CN104245691A (zh) * 2012-03-21 2014-12-24 默克专利股份有限公司 制备苯并[1,2-b;4,5-b’]二噻吩-4,8-二羧酸或其2,3-二氢衍生物的方法
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9926312B2 (en) 2013-10-01 2018-03-27 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (fr) * 1990-09-13 1992-04-02 Beecham Group Plc Urees d'indole utilisees comme antagonistes de recepteur de 5-ht
WO1993018028A1 (fr) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Derives d'indole utilises comme antagonistes de 5ht¿1c?
WO1994004533A1 (fr) * 1992-08-20 1994-03-03 Smithkline Beecham Plc DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B?
WO1994018196A1 (fr) * 1993-02-10 1994-08-18 The Wellcome Foundation Limited Composes heteroaromatiques a activite antipsychotique
WO1994022871A1 (fr) * 1993-03-29 1994-10-13 Smithkline Beecham Plc DERIVES THIENO-INDOLIQUES UTILISES COMME ANTAGONISTES DE 5HT2c ET DE 5HT2b
WO1994024125A1 (fr) * 1993-04-08 1994-10-27 Boehringer Ingelheim Italia S.P.A. Nouveaux derives d'indole utilises en tant que ligands de 5-ht1a et/ou de 5-ht2
WO1995001976A1 (fr) * 1993-07-06 1995-01-19 Smithkline Beecham Plc Derives indoliniques utilises comme antagonistes de 5ht¿2c?

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005170A1 (fr) * 1990-09-13 1992-04-02 Beecham Group Plc Urees d'indole utilisees comme antagonistes de recepteur de 5-ht
WO1993018028A1 (fr) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Derives d'indole utilises comme antagonistes de 5ht¿1c?
WO1994004533A1 (fr) * 1992-08-20 1994-03-03 Smithkline Beecham Plc DERIVES D'INDOLE CONDENSES UTILISES COMME ANTAGONISTES DES RECEPTEURS 5HT2C et 5HT¿2B?
WO1994018196A1 (fr) * 1993-02-10 1994-08-18 The Wellcome Foundation Limited Composes heteroaromatiques a activite antipsychotique
WO1994022871A1 (fr) * 1993-03-29 1994-10-13 Smithkline Beecham Plc DERIVES THIENO-INDOLIQUES UTILISES COMME ANTAGONISTES DE 5HT2c ET DE 5HT2b
WO1994024125A1 (fr) * 1993-04-08 1994-10-27 Boehringer Ingelheim Italia S.P.A. Nouveaux derives d'indole utilises en tant que ligands de 5-ht1a et/ou de 5-ht2
WO1995001976A1 (fr) * 1993-07-06 1995-01-19 Smithkline Beecham Plc Derives indoliniques utilises comme antagonistes de 5ht¿2c?

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLUDZINSKI,P. ET AL.: "2,3-Dialkyl(dimethylamino)indoles: Intersctions with 5HT1,5HT2, and Rat Stomach Fundal Serotonin Receptors", J.MED.CHEM., vol. 29, WASHINGTON, pages 2415 - 2418 *
FORBES,I.T. ET AL.: "N-(1-Methyl-5-indolyl)-N'-(3-pyridyl)urea Hydrochloride : The first selective 5-HT1c Receptro Antagonist", J.MED.CHEM., vol. 36, WASHINGTON, pages 1104 - 1107 *

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653304B2 (en) 2000-02-11 2003-11-25 Bristol-Myers Squibb Co. Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
WO2001058869A3 (fr) * 2000-02-11 2002-01-24 Bristol Myers Squibb Co Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
WO2001058869A2 (fr) * 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Modulateurs de recepteurs aux cannabinoides, leurs procedes de preparation et utilisations de modulateurs de recepteurs aux cannabinoides pour le traitement de maladies respiratoires et non respiratoires
JP2004502642A (ja) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー カンナビノイドレセプターモジュレーター、それらの製造方法、および呼吸系および非呼吸系疾患の処置のためのカンナビノイドレセプターモジュレーターの使用
US6900323B2 (en) 2000-02-22 2005-05-31 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US6632819B1 (en) 2000-02-22 2003-10-14 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
KR100880586B1 (ko) * 2000-10-27 2009-01-30 엘비온 게엠베하 7-아자인돌을 포함하는 약제학적 조성물
DE10053275A1 (de) * 2000-10-27 2002-05-02 Dresden Arzneimittel Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
WO2002034747A1 (fr) * 2000-10-27 2002-05-02 Elbion Ag Nouveaux 7-azaindoles, leur utilisation en tant qu'inhibiteurs de la phosphodiesterase 4 et leur procede de production
KR100837099B1 (ko) * 2000-10-27 2008-06-13 엘비온 아게 7-아자인돌 및 이의 제조방법
US7169787B2 (en) 2000-10-27 2007-01-30 Elbion Ag 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
US7501420B2 (en) 2001-02-02 2009-03-10 Bristol-Myers Squibb Company Composition and antiviral of substituted azaindoleoxoacetic piperazine derivatives
US7662823B2 (en) 2001-02-02 2010-02-16 Bristol-Myers Squibb Company Pharmaceutical formulations of substituted azaindoleoxoacetic piperazine derivatives
US7354924B2 (en) 2001-02-02 2008-04-08 Bristol-Myers Squibb Company Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CZ303750B6 (cs) * 2001-02-02 2013-04-17 Bristol-Myers Squibb Company Prostredky obsahující substituované deriváty azaindoloxoacetylpiperazinu a jejich antivirová aktivita
WO2002062423A1 (fr) * 2001-02-02 2002-08-15 Bristol-Myers Squibb Company Composition et activite antivirale de derives de piperazine azaindoleoxoacetique substitues
CN100384423C (zh) * 2001-02-02 2008-04-30 布里斯托尔-迈尔斯斯奎布公司 取代的氮杂吲哚氧代乙酰哌嗪衍生物的组合物和抗病毒活性
US6825201B2 (en) 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US7531552B2 (en) 2002-02-14 2009-05-12 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic pyrrolidine derivatives
US7714019B2 (en) 2002-02-14 2010-05-11 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic pyrrolidine derivatives
US7037913B2 (en) 2002-05-01 2006-05-02 Bristol-Myers Squibb Company Bicyclo 4.4.0 antiviral derivatives
US7348337B2 (en) 2002-05-28 2008-03-25 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7915283B2 (en) 2002-05-28 2011-03-29 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US6900206B2 (en) 2002-06-20 2005-05-31 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
EP2801576A1 (fr) 2002-08-07 2014-11-12 Bristol-Myers Squibb Company Composition et activité antivirale de dérivés de pipérazine azaindoléoxoacétique substitués
EP2497770A1 (fr) 2002-08-07 2012-09-12 Bristol-Myers Squibb Company Composition et activité antivirale de dérivés de pipérazine azaindoléoxoacétique substitués
EP2975038A1 (fr) 2002-08-07 2016-01-20 Bristol-Myers Squibb Company Composition et activite antivirale de derives de piperazine azaindoleoxoacetique substitues
US7211583B2 (en) 2003-04-24 2007-05-01 Elbion Ag 7-azaindoles and the use thereof as therapeutic agents
WO2004094416A1 (fr) * 2003-04-24 2004-11-04 Elbion Ag 7-azaindoles et leur utilisation comme produits therapeutiques
US7947705B2 (en) * 2003-04-24 2011-05-24 Biotie Therapies Gmbh 7-azaindoles and the use thereof as therapeutic agents
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
US8039486B2 (en) 2003-07-01 2011-10-18 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
US7902204B2 (en) 2003-11-26 2011-03-08 Bristol-Myers Squibb Company Diazaindole-dicarbonyl-piperazinyl antiviral agents
US7504509B2 (en) 2003-12-19 2009-03-17 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US7728140B2 (en) 2003-12-24 2010-06-01 Pfizer Italia S.R.L. Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them
US7888508B2 (en) 2003-12-24 2011-02-15 Pfizer Italia S.R.L. Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors
US8198298B2 (en) 2003-12-24 2012-06-12 Pfizer Italia S.R.L. Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors
US8106069B2 (en) 2003-12-24 2012-01-31 Pfizer Italia S.R.L. Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them
FR2865208A1 (fr) * 2004-01-16 2005-07-22 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
US7589201B2 (en) 2004-01-16 2009-09-15 Sanofi-Aventis Derivatives of 1,4-diazabicyclo[3.2.1]octanecarboxamide, preparation method thereof and use of same in therapeutics
WO2005077955A1 (fr) * 2004-01-16 2005-08-25 Sanofi-Aventis Derives de 1,4-diazabicyclo[3.2.1]octanecarboxamide, leur preparation et leur application en therapeutique
US7589206B2 (en) 2004-06-09 2009-09-15 Glaxo Group Limited Pyrrolopyridine derivatives
JP2008503473A (ja) * 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Ｃ−ｋｉｔ活性を調節する化合物
WO2006009755A2 (fr) * 2004-06-17 2006-01-26 Plexxikon, Inc. Composes modulant l'activite de c-kit
WO2006009755A3 (fr) * 2004-06-17 2006-04-20 Plexxikon Inc Composes modulant l'activite de c-kit
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US7829711B2 (en) 2004-11-09 2010-11-09 Bristol-Myers Squibb Company Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-C]pyridine-3-yl]-ethane-1,2-dione
EP2202222A2 (fr) 2005-11-08 2010-06-30 Laboratorios Del Dr. Esteve, S.A. Dérivés d'indène, leur préparation et leur utilisation en tant que médicaments
US8217041B2 (en) 2005-11-08 2012-07-10 Laboratories del Sr. Esteve, S.A. Indene derivatives, their preparation and use as medicaments
ES2274725B1 (es) * 2005-11-08 2008-04-01 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
ES2274725A1 (es) * 2005-11-08 2007-05-16 Laboratorios Del Dr. Esteve, S.A. Indeno derivados, su preparacion y su uso como medicamentos.
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807676B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-Piperazine and Piperidine derivatives as antiviral agents
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US8138210B2 (en) 2006-07-31 2012-03-20 Laboratorios Del Dr. Esteve, S.A. Substituted indanyl sulfonamide compounds, their preparation and use as medicaments
US9169250B2 (en) 2006-11-22 2015-10-27 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9487515B2 (en) 2006-11-22 2016-11-08 Plexxikon Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US9469640B2 (en) 2007-07-17 2016-10-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US10426760B2 (en) 2007-07-17 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9844539B2 (en) 2007-07-17 2017-12-19 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US7964603B2 (en) 2007-07-19 2011-06-21 Laboratorios Del Dr. Esteve, S.A. Substituted tetrahydro-quinoline-sulfonamide compounds, their preparation and use as medicaments
US9663517B2 (en) 2009-04-03 2017-05-30 Plexxikon Inc. Compositions and uses thereof
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US9096593B2 (en) 2009-11-06 2015-08-04 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9624213B2 (en) 2011-02-07 2017-04-18 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US11337976B2 (en) 2011-02-07 2022-05-24 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US12076322B2 (en) 2011-02-07 2024-09-03 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US8865735B2 (en) 2011-02-21 2014-10-21 Hoffman-La Roche Inc. Solid forms of a pharmaceutically active substance
CN104245691A (zh) * 2012-03-21 2014-12-24 默克专利股份有限公司 制备苯并[1,2-b;4,5-b’]二噻吩-4,8-二羧酸或其2,3-二氢衍生物的方法
US9216994B2 (en) 2012-03-21 2015-12-22 Merck Patent Gmbh Process for preparing benzo[1,2-b;4,5-b′]dithiophene-4,8-dicarboxylic acid or its 2,3-dihydro derivative
US9695169B2 (en) 2012-05-31 2017-07-04 Plexxikon Inc. Synthesis of heterocyclic compounds
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
US9926312B2 (en) 2013-10-01 2018-03-27 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US10072005B2 (en) 2013-10-01 2018-09-11 Eisai R&D Management Co., Ltd. 4-azaindole derivatives
US10421756B2 (en) 2015-07-06 2019-09-24 Rodin Therapeutics, Inc. Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase
US10919902B2 (en) 2015-07-06 2021-02-16 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US11858939B2 (en) 2015-07-06 2024-01-02 Alkermes, Inc. Hetero-halo inhibitors of histone deacetylase
US10696673B2 (en) 2017-01-11 2020-06-30 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US10793567B2 (en) 2017-01-11 2020-10-06 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225479B2 (en) 2017-01-11 2022-01-18 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US11286256B2 (en) 2017-01-11 2022-03-29 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US10519149B2 (en) 2017-01-11 2019-12-31 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11987580B2 (en) 2017-01-11 2024-05-21 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
US9951069B1 (en) 2017-01-11 2018-04-24 Rodin Therapeutics, Inc. Bicyclic inhibitors of histone deacetylase
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase
US11912702B2 (en) 2017-08-07 2024-02-27 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Also Published As

Publication number Publication date
GB9420521D0 (en) 1994-11-30

Similar Documents

Publication Publication Date Title
WO1996011929A1 (fr) Derives biheteroaryl-carbonyles et carboxamides possedant une activite antagoniste de 5ht 2c/2b
US5620974A (en) 5,11-dihyro-6H-dipyrido[3,2-B:2',3'-e][1,3]diazepines and their use in the prevention or treatment of HIV infection
US5922733A (en) Pyridil carboxamides as 5HT2B/2C receptor antagonists
EP0465254B1 (fr) Composés condensés de thiophen et leur usage
JP4216197B2 (ja) 新規ピリジン及びキノリン誘導体
US5919932A (en) Biphenylamide derivatives as 5HT1D antagonists
US5866586A (en) CNS-active pyridinylurea derivatives
JP2004509894A (ja) 置換アゼピノ［４，５−ｂ］インドリン誘導体
AU3036000A (en) Compounds
EP1003738B1 (fr) Composes bicycliques servant de ligands pour les recepteurs 5-ht1
NZ238141A (en) 1,2,3,4,4a,10b-hexahydro-6-(sulphonamidophenyl)benzo(c)(1,6)naphthyridine derivatives, preparation and pharmaceutical compositions thereof
IL115236A (en) History 2-] Dihydro-2-thi (oxobenzazolyl-alkyl [tetrahydro-pyrido-] B-3,4 [and] B-4,3 [indole and pharmaceutical preparations containing or
JPH09501171A (ja) ５ｈｔ１ｄ受容体アンタゴニストとしてのアミド誘導体
WO1997008167A1 (fr) Antagonistes des recepteurs 5ht2c et 5ht¿2b?
EP1228043B1 (fr) Derives d'isoquinoline et de quinazoline dotes d'une activite combinee de recepteur 5ht1a, 5ht1b et 5ht1d
US6313145B1 (en) Indoline derivatives useful as 5-HT-2C receptor antagonists
EP0126970A2 (fr) Dérivés de thiénopyridine anxiolytiques et antidépresseurs
KR20010022658A (ko) 3-치환된 3,4,5,7-테트라히드로-피롤로[3'4':4,5]티에노[2,3-ｄ]피리미딘 유도체, 그의 제법 및 5ｈｔ길항제로서의 용도
EP0912554B1 (fr) Derives de l'indoline utiles comme antagonistes des recepteurs 5ht-2c
EP0757687A1 (fr) Derives tricycliques antagonistes de 5ht2c et de 5ht2b
JP2001220390A (ja) 縮合ピラゾール誘導体
JPH09508637A (ja) ５ｈｔ２ｂレセプタ拮抗薬縮合インドール
US6166034A (en) Spiro piperidine derivatives as 5HT1D receptor antagonists
SK137597A3 (en) 1-£'omega'-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same
US6214826B1 (en) Pyridazino quinoline compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载